View Older Stories View More Recent Stories

May 26, 2022 05:04PM PDS Biotechnology (PDSB) Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO
May 26, 2022 05:02PM PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
May 26, 2022 05:01PM PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022
May 25, 2022 08:00AM PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting
May 18, 2022 08:00AM PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development
May 17, 2022 08:00AM PDS Biotech to Participate at Upcoming Investor Conferences
May 11, 2022 07:00AM PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results
Apr 28, 2022 08:00AM PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results
Apr 27, 2022 10:01AM PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 20, 2022 08:00AM PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress
Apr 19, 2022 08:09AM PDS Biotechnology (PDSB) Granted $1.2M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
Apr 19, 2022 08:00AM PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
Apr 8, 2022 08:00AM PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2022 07:00AM PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results
Mar 22, 2022 07:30PM PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
Mar 15, 2022 07:46AM PDS Biotech (PDSB) Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Mar 15, 2022 07:45AM PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
Mar 9, 2022 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results
Mar 1, 2022 08:00AM PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference
Feb 24, 2022 10:10AM PDS Biotechnology (PDSB) Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
Feb 24, 2022 10:10AM PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
Feb 15, 2022 08:07AM PDS Biotechnology (PDSB) Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer
Feb 15, 2022 08:00AM PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer
Feb 2, 2022 08:02AM PDS Biotechnology (PDSB) Reports Prelim Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA
Feb 2, 2022 08:00AM PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Jan 27, 2022 08:06AM PDS Biotechnology (PDSB) Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
Jan 27, 2022 08:00AM PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
Jan 18, 2022 08:00AM PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference
Jan 12, 2022 08:00AM PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium
Jan 10, 2022 07:08AM PDS Biotechnology (PDSB) Granted US Patent for HPV16 Immunotherapy
Jan 10, 2022 07:00AM PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy
Jan 5, 2022 08:00AM PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference
Dec 23, 2021 04:00PM PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dec 6, 2021 08:30AM PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination
Nov 10, 2021 07:00AM PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
Nov 8, 2021 08:33AM PDS Biotechnology (PDSB) Announces Licensing Agreement for Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
Nov 8, 2021 08:30AM PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
Nov 1, 2021 08:30AM PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine
Oct 27, 2021 08:30AM PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
Oct 21, 2021 04:30PM PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 21, 2021 07:30AM PDS Biotechnology (PDSB) Temporarily Suspend Phase 2 Clinical Trial of PDS0101-Based Combination
Oct 21, 2021 07:30AM PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination
Oct 13, 2021 04:30PM PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
Oct 6, 2021 08:31AM PDS Biotechnology (PDSB) Welcomes Matthew Hill as Chief Financial Officer
Oct 6, 2021 08:30AM PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer
Oct 4, 2021 08:30AM PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
Sep 27, 2021 08:30AM PDS Biotechnology to Present at the Benzinga Healthcare Conference
Sep 22, 2021 08:30AM PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 20, 2021 08:32AM PDS Biotechnology (PDSB) Achieves Safety Milestone for First 12 Patients in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA
Sep 20, 2021 08:30AM PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
View More Recent Stories View Older Stories